Edition #4: Living Longer Isn’t the Goal Anymore
For a century, medicine optimized for the wrong variable.
Your company’s health benefits were designed for a workforce that gets sick at 60 and retires at 65.
That model is being dismantled in laboratories right now. Not in press releases. In clinical trials.
The Signal: Medicine Finally Asked the Right Question
For most of medical history, the goal was simple: keep people alive longer.
It worked. Global life expectancy went from 47 years in 1900 to over 73 today. But the system that achieved that created a problem nobody planned for: millions of people living longer in worse condition. More years. Fewer of them good.
The United States is the clearest example. Americans spend more per capita on healthcare than any other country. And yet, life expectancy in the US peaked around 2014 and has been declining since. The leading causes of death shifted from infectious disease to chronic conditions: heart disease, diabetes, Alzheimer’s, obesity-related illness. The system got very good at keeping people alive with those conditions. It never figured out how to prevent them at scale.
That’s the distinction between lifespan and healthspan.
Lifespan is how long you live. Healthspan is how many of those years you spend with full physical and cognitive capacity. The gap between the two is where most people spend their final decade, managing chronic disease, losing mobility, watching cognitive function decline.
In the United States alone, chronic disease is projected to cost $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical costs and nearly $900 billion per year in lost productivity by 2039, according to the Partnership to Fight Chronic Disease. 90% of the $4.9 trillion the US spends annually on healthcare goes to people with chronic and mental health conditions, according to the CDC.
The system optimized for the wrong variable for a century.
Jun Axup Penman, longevity researcher and Singularity University expert, put it plainly at the Executive Program in April 2026: nothing proven consistently increases healthspan today. We have lifestyle interventions. We have drugs that manage symptoms. Therapies that reliably extend the years you spend at full capacity don’t exist yet.
That’s the problem the next generation of biotech is working on. And for the first time, the tools available to attack it are fundamentally different.
The roadmap, according to Axup Penman: today, researchers increase healthspan with lifestyle and drugs. In the next five years, replacement and reprogramming therapies enter the picture. The bottleneck isn’t scientific. It’s running clinical trials fast enough to prove what works.
Researchers are using AI to close that gap. A drug discovery process that took a decade now takes 18 months. That compression changes what’s possible in the next five years, not the next twenty.
The Application: What’s Already in the Pipeline
This isn’t future science. These are programs in clinical trials now.
Annovis Bio, Buntanetap. Published Phase 2/3 results in Nature NPJ Dementia in April 2026. A once-daily oral pill targeting amyloid, tau, alpha-synuclein, and TDP-43 simultaneously. Every previous Alzheimer’s drug targeted a single protein. Buntanetap attacks upstream, before the damage forms. Statistically significant results in mild Alzheimer’s patients with confirmed biomarkers. Phase 3 results expected Q1 2027.
Insilico Medicine. First drug designed with AI to reach Phase 2 clinical trials, for idiopathic pulmonary fibrosis. Designed in 18 months. A traditional drug discovery process takes 4 to 6 years to reach the same stage. The company went public in Hong Kong with a $2.7B market cap.
Retro Biosciences, Altos Labs, NewLimit, Calico. Twenty companies working on age reversal through epigenetic reprogramming. Raymond McCauley, founding faculty at Singularity University, frames the science this way: disrupting epigenetics accelerates aging. Repairing it reverses aging. These companies are working on the repair.
The cost of reading the human genome. In 2001, sequencing a human genome cost $100 million. Today it costs under $200. That curve dropped faster than Moore’s Law. At that price, personalized medicine at scale stops being a research concept and becomes an engineering problem.
The market is responding. Longevity biotech captured $3.74 billion in Q1 2026 alone. 56% more than Q1 2025. The sector is projected to grow from $9.86B in 2025 to $29.7B in 2034.
The Noise: Confusing the Two Categories
Lifestyle interventions work. Exercise, sleep, nutrition, stress management. The evidence is solid and the tools are accessible. That’s not noise.
The noise is treating those interventions as a substitute for understanding what’s happening in clinical science.
A CEO who runs marathons and takes magnesium at night isn’t wrong. But if that same CEO dismisses longevity biotech as “wellness stuff,” they’re conflating two categories that operate on completely different timelines, mechanisms, and business implications.
Lifestyle interventions optimize the system you have. What’s happening in labs right now is about reprogramming the system itself.
Those are not the same conversation. And the leaders who treat them as one are going to be surprised by what Phase 3 results look like in 2027.
The Question
Your workforce strategy was designed for people who retire at 65. If healthspan extends by a decade, which assumptions in your talent model, your benefits structure, and your succession planning are no longer accurate?
Now What?
Audit your benefits assumptions. Most corporate health plans were designed for a workforce that peaks at 50 and declines at 60. The economics of those plans change materially if employees work productively at 70. Start the conversation with your CFO and HR lead now, before it becomes urgent.
Map your sector’s exposure. If you operate in pharma, insurance, medical devices, or healthcare-adjacent services, the shift from symptom management to healthspan optimization changes your competitive landscape within five years. The companies building for that world are already funded.
Watch the drug discovery timeline. The 18 months from Insilico is the new benchmark, not the exception. The companies that will lead pharma in 2035 are being built today with AI at the core of their R&D.
Take the Alzheimer’s signal seriously for workforce planning. 55 million people globally live with dementia. Most organizations have no strategy for the caregiving burden this places on their workforce today, let alone what happens if effective treatments arrive and change the cost curve entirely.
What I’m Watching
South Korea executing a national PQC migration. The Ministry of Science and ICT expanded its post-quantum cryptography program to telecoms, finance, transportation, defense, and space. Real contracts, specific companies, defined timelines. When a government moves at this level, it sets the compliance baseline for companies doing business in that country. LATAM doesn’t have an equivalent program. Its trading partners do.
Tesla started Optimus production in Q2 2026. At its Fremont plant, replacing legacy auto lines. The price floor for humanoid robots is being set right now. Every manufacturing cost model that doesn’t include this variable is already outdated.
The genome cost curve keeps falling. At under $200 per genome today, the question for every large employer isn’t whether genomic data will factor into occupational health decisions. It’s who sets the rules when it does.
This is Wavelens. Emerging tech without the hype. Real signals for strategic decisions.
If this edition helped you see something you weren’t seeing before, forward it to one leader in your network who needs to be in this conversation.
Subscribe at newsletter.wavelens.ai so you don’t miss the next edition. Follow Wavelens on LinkedIn for daily signals on the convergence.
Javier D’Ovidio
Wavelens